Legend Biotech Q1 EPS Estimate Decreased by HC Wainwright

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) – Research analysts at HC Wainwright reduced their Q1 2026 EPS estimates for shares of Legend Biotech in a report issued on Monday, March 16th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.04) per share for the quarter, down from their prior estimate of $0.04. HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Legend Biotech’s FY2026 earnings at $0.42 EPS.

A number of other brokerages have also recently weighed in on LEGN. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Legend Biotech in a research report on Monday, December 29th. Cantor Fitzgerald cut their price objective on Legend Biotech from $75.00 to $74.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 17th. Raymond James Financial reaffirmed an “outperform” rating on shares of Legend Biotech in a research report on Monday, February 23rd. Truist Financial set a $70.00 target price on Legend Biotech in a research note on Tuesday, March 10th. Finally, Royal Bank Of Canada dropped their target price on Legend Biotech from $66.00 to $62.00 and set an “outperform” rating on the stock in a report on Wednesday, March 11th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $58.31.

Legend Biotech Trading Down 1.8%

Shares of LEGN stock opened at $18.21 on Thursday. The company has a market cap of $3.37 billion, a PE ratio of -22.76 and a beta of 0.07. The company’s fifty day simple moving average is $19.20 and its 200-day simple moving average is $25.87. Legend Biotech has a 52 week low of $16.24 and a 52 week high of $45.30.

Legend Biotech (NASDAQ:LEGN) last announced its quarterly earnings results on Tuesday, March 10th. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.18. Legend Biotech had a negative net margin of 28.86% and a negative return on equity of 21.93%. The firm had revenue of $306.30 million for the quarter, compared to analysts’ expectations of $310.21 million. During the same period in the previous year, the company posted $0.07 earnings per share. Legend Biotech’s revenue was up 64.2% compared to the same quarter last year.

Institutional Trading of Legend Biotech

A number of hedge funds have recently made changes to their positions in LEGN. Clearstead Advisors LLC boosted its stake in Legend Biotech by 76.5% during the 3rd quarter. Clearstead Advisors LLC now owns 847 shares of the company’s stock valued at $28,000 after acquiring an additional 367 shares during the last quarter. Parallel Advisors LLC lifted its position in shares of Legend Biotech by 171.9% during the third quarter. Parallel Advisors LLC now owns 1,047 shares of the company’s stock worth $34,000 after purchasing an additional 662 shares during the last quarter. OFI Invest Asset Management lifted its position in shares of Legend Biotech by 102.6% during the third quarter. OFI Invest Asset Management now owns 1,228 shares of the company’s stock worth $40,000 after purchasing an additional 622 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its stake in Legend Biotech by 1,730.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,569 shares of the company’s stock worth $78,000 after purchasing an additional 3,374 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Legend Biotech in the second quarter worth about $78,000. Institutional investors and hedge funds own 70.89% of the company’s stock.

About Legend Biotech

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.